ONO 2160/carbidopa

Drug Profile

ONO 2160/carbidopa

Alternative Names: Carbidopa/levodopa prodrug; Carbidopa/ONO-2160; Levodopa prodrug/carbidopa

Latest Information Update: 30 Aug 2016

Price : $50

At a glance

  • Originator Ono Pharmaceutical
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 19 Apr 2016 Phase-I development is ongoing in Japan
  • 30 Nov 2014 Ono Pharmaceuticals completes enrolment in its phase I trial for Parkinson's disease in Japan (PO) after November 2014 (JapicCTI142702)
  • 01 Nov 2014 Ono Pharmaceuticals initiates enrolment in a phase I trial for Parkinson's disease in Japan (PO) (JapicCTI142702 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top